2剂赛尼哌预防肾移植术后急性排斥反应的应用研究

TWO DOSES REGIMEN OF DACLIZUMAB IN THE PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION

目的 :探讨赛尼哌在预防同种肾异体移植术后急性排斥反应的作用。方法 :回顾分析了已随访 1年的 32例应用 2剂赛尼哌患者的临床效果 ,并以同期肾移植 92例作为对照组。结果 :赛尼哌组在 3月内急性排斥反应发生率 (3.1% )显著低于对照组 (2 3.9% ) (P <0 .0 5 ) ,在感染及副作用方面与对照组无显著性差异。结论 :2剂赛尼哌加上CsA ,MMP ,Pred联合应用的免疫抑制方案对预防同种尸体肾移植受者的急性排斥反应的发生是安全有效的。

Objective:To investigate its use in daclizumab in the prevention of acute rejection in renal transplant recipients.Methods:This was a non-randomized and retrospective study. A total of 32 renal transplant recipients were studied and followed. A simultaneous cohort of 92 renal transplant recipients served as control group.Results:All the patients received a follow-up of 12 months at least. Acute rejection rates were lower in the daclizumab group(3.1%) as compared to the control group(23.9%) within 3 months( P <0.05). No difference in infection episodes and adverse events between daclizumab group and control group.Conclusion:The treatment consisting of daclizumab, MMF, CsA and Pred was effective in the prevention of acute rejection in renal transplant recipients.